Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis

新型结核分枝杆菌 mRNA 疫苗的开发

基本信息

  • 批准号:
    10625373
  • 负责人:
  • 金额:
    $ 42.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-05-20 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract Tuberculosis remains one of the top ten leading causes of death worldwide (1). Based on the most current information from WHO 2020 report, in 2019 an estimated 1.4 million people died from TB and approximately 10,000,000 fell ill (2). The COVID-19 pandemic has led to massive decreases in TB case identification and Stop TB estimates an additional 1.4 million TB deaths will be registered over the next 4 years (3, 4). This, together with the growing threat of drug-resistant TB and the co-epidemics of TB with HIV and diabetes makes ending the TB epidemic more crucial than ever before. A vaccine that prevents adolescents and adults from acquiring, developing, and transmitting TB would be the single most cost-effective tool in ending the TB epidemic (5). The TuBerculosis Vaccine Initiative (TBVI) and Treatment Action Group (TAG) TB Vaccine Pipelines report twelve subunit vaccines including recombinant protein/adjuvant and viral vector vaccines spanning from preclinical through Phase 3 development (6, 7). Of these, nine include Ag85 (Ag85A or B) and six include ESAT6. The highly limited antigenic and immunological diversity present in the pipeline is a significant gap in efforts to develop a novel, effective vaccine. The proposed research is intended to bring needed antigenic and platform diversity to the pre-clinical TB vaccine pipeline using Moderna’s cutting-edge mRNA vaccine technology and expertise. Within the R61 phase of this program, we will first optimize mycobacterial antigen sequences for expression in mammalian cells using Moderna’s proprietary learnings and algorithms. These principles will be applied to the development of three candidate mRNA vaccines, including 1) an antigen cassette previously shown to induce protection in animal models when delivered as a protein plus adjuvant, 2) a new antigen cassette including novel antigens, and 3) the M72 antigen shown to induce protection in humans when delivered as recombinant protein with the AS01E adjuvant. We will then use data from murine immunogenicity and protection studies to select the two best candidates for advancement into the R33 phase. Within the R33 phase, we will use the guinea pig challenge model to downselect to a final lead candidate for further advancement. Once a final lead candidate is selected, additional studies will be conducted to further characterize the candidate, including protection in genetically diverse mice and an immunogenicity study in nonhuman primates to optimize the vaccination regimen for clinical use. By the end of this program, we will have a novel lead vaccine candidate ready for advancement into IND- enabling studies and early development as a vaccine to prevent TB disease in adults and adolescents.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KENT E. KESTER其他文献

KENT E. KESTER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KENT E. KESTER', 18)}}的其他基金

Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis
新型结核分枝杆菌 mRNA 疫苗的开发
  • 批准号:
    10440618
  • 财政年份:
    2022
  • 资助金额:
    $ 42.23万
  • 项目类别:

相似海外基金

Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 42.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The impact of changes in social determinants of health on adolescent and young adult mental health during the COVID-19 pandemic: A longitudinal study of the Asenze cohort in South Africa
COVID-19 大流行期间健康社会决定因素的变化对青少年和年轻人心理健康的影响:南非 Asenze 队列的纵向研究
  • 批准号:
    10755168
  • 财政年份:
    2023
  • 资助金额:
    $ 42.23万
  • 项目类别:
A Priority Setting Partnership to Establish a Patient, Caregiver, and Clinician-identified Research Agenda for Adolescent and Young Adult Cancer in Canada
建立优先合作伙伴关系,以建立患者、护理人员和临床医生确定的加拿大青少年和年轻人癌症研究议程
  • 批准号:
    480840
  • 财政年份:
    2023
  • 资助金额:
    $ 42.23万
  • 项目类别:
    Miscellaneous Programs
Incidence and Time on Onset of Cardiovascular Risk Factors and Cardiovascular Disease in Adult Survivors of Adolescent and Young Adult Cancer and Association with Exercise
青少年和青年癌症成年幸存者心血管危险因素和心血管疾病的发病率和时间以及与运动的关系
  • 批准号:
    10678157
  • 财政年份:
    2023
  • 资助金额:
    $ 42.23万
  • 项目类别:
Fertility experiences among ethnically diverse adolescent and young adult cancer survivors: A population-based study
不同种族青少年和年轻成年癌症幸存者的生育经历:一项基于人群的研究
  • 批准号:
    10744412
  • 财政年份:
    2023
  • 资助金额:
    $ 42.23万
  • 项目类别:
Treatment development for refractory leukemia using childhood/adolescent, and young adult leukemia biobank
利用儿童/青少年和青年白血病生物库开发难治性白血病的治疗方法
  • 批准号:
    23K07305
  • 财政年份:
    2023
  • 资助金额:
    $ 42.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular design of Two-Way Player CAR-T cells to overcome disease/antigen heterogeneity of childhood, adolescent, and young adult cancers
双向 CAR-T 细胞的分子设计,以克服儿童、青少年和年轻成人癌症的疾病/抗原异质性
  • 批准号:
    23H02874
  • 财政年份:
    2023
  • 资助金额:
    $ 42.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Effects of adolescent social isolation on adult decision making and corticostriatal circuitry
青少年社会隔离对成人决策和皮质纹状体回路的影响
  • 批准号:
    10756652
  • 财政年份:
    2023
  • 资助金额:
    $ 42.23万
  • 项目类别:
Adolescent trauma produces enduring disruptions in sleep architecture that lead to increased risk for adult mental illness
青少年创伤会对睡眠结构产生持久的破坏,从而导致成人精神疾病的风险增加
  • 批准号:
    10730872
  • 财政年份:
    2023
  • 资助金额:
    $ 42.23万
  • 项目类别:
Using Tailored mHealth Strategies to Promote Weight Management among Adolescent and Young Adult Cancer Survivors
使用量身定制的移动健康策略促进青少年和年轻癌症幸存者的体重管理
  • 批准号:
    10650648
  • 财政年份:
    2023
  • 资助金额:
    $ 42.23万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了